ExoDx(EPI)前列腺智能评分在初始活检中预测高级别前列腺癌的三项独立前瞻性研究临床性能
该研究汇总三项独立前瞻性验证研究(n=1212)数据,评估尿液外泌体RNA检测ExoDx(EPI)在初始活检决策中区分高级别前列腺癌(≥GG2)与低级别(GG1)及良性病理的性能。EPI的AUC为0.70,优于PSA(0.56)、PCPT-RC(0.62)和ERSPC(0.59)(均P<0.001)。采用15.6截断值可避免23%的前列腺活检和30%的“不必要”活检,NPV为90%。
要点
- EPI在初始活检人群中区分≥GG2与GG1/良性的AUC为0.70,优于PSA等标准工具。
- 截断值15.6可避免23%总活检和30%不必要活检,NPV达90%。
- EPI为无创尿液外泌体RNA检测,可独立于PSA指导活检决策。
核心结论
- EPI是一种无创、易用的尿液外泌体RNA检测,已在三项独立前瞻性多中心临床试验(共1212例)中验证,能区分高级别(≥GG2)与低级别(GG1)前列腺癌及良性病变,并有效指导活检决策。
研究设计与样本
- 汇总两项前瞻性多中心验证研究及一项临床效用研究的对照组数据,共纳入1212例初始活检受试者,中位年龄63岁,中位PSA 5.2 ng/mL。
主要发现
- EPI的AUC为0.70,优于PSA(0.56)、PCPT-RC(0.62)和ERSPC(0.59),差异均P<0.001。
- 采用验证截断值15.6可避免23%的所有前列腺活检和30%的“不必要”(良性或Gleason 6/GG1)活检,NPV为90%。
关键数值与推荐
- EPI截断值15.6用于区分≥GG2与GG1及良性病理,NPV为90%,可避免23%总活检和30%不必要活检。
临床怎么用
- 对于PSA 2-10 ng/mL、≥50岁且面临初始活检决策的男性,EPI检测可辅助识别高级别前列腺癌风险,减少不必要活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine exosomes. The EPI test stratifies patients for risk of high-grade prostate cancer (HGPC; ≥ Grade Group 2 [GG] PC) in men ≥ 50 years with equivocal prostate-specific antigen (PSA) (2-10 ng/mL). Here, we present a pooled meta-analysis from three independent prospective-validation studies in men presenting for initial biopsy decision. METHODS: Pooled data from two prospective multi-site validation studies and the control arm of a clinical utility study were analyzed. Performance was evaluated using the area under the receiver-operating characteristic curve (AUC), negative predictive value (NPV), positive predictive value (PPV), sensitivity, and specificity for discriminating ≥ GG2 from GG1 and benign pathology. RESULTS: The combined cohort (n = 1212) of initial-biopsy subjects had a median age of 63 years and median PSA of 5.2 ng/mL. The EPI AUC (0.70) was superior to PSA (0.56), Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) (0.62), and The European Randomized Study of Screening for Prostate Cancer (ERSPC) (0.59), (all p-values <0.001) for discriminating GG2 from GG1 and benign histology. The validated cutoff of 15.6 would avoid 23% of all prostate biopsies and 30% of "unnecessary" (benign or Gleason 6/GG1) biopsies, with an NPV of 90%. CONCLUSIONS: EPI is a noninvasive, easy-to-use, urine exosome-RNA assay that has been validated across 3 independent prospective multicenter clinical trials with 1212 subjects. The test can discriminate high-grade (≥GG2) from low-grade (GG1) cancer and benign disease. EPI effectively guides the biopsy-decision process independent of PSA and other standard-of-care factors.
引用
- Margolis E, Brown G, Partin A, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2021. PMID: 34593984. doi:10.1038/s41391-021-00456-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。